Folsom A R, Iso H, Sprafka J M, Edlavitch S A, Luepker R V
Division of Epidemiology, School of Public Health, University of Minnesota, Minneapolis 55455.
Am Heart J. 1988 Sep;116(3):827-30. doi: 10.1016/0002-8703(88)90344-4.
The efficacy of aspirin to prevent ischemic cardiovascular disease has received considerable attention recently. To determine the prevalence of aspirin use for cardiovascular disease prevention, the Minnesota Heart Survey examined population-based samples of Twin Cities' adults in 1981 to 82 and 1985 to 86. Over the 4-year period, reported use of aspirin for cardiovascular disease prophylaxis increased from 0.6% to 2.4% in women (p less than 0.05) and from 1.7% to 3.3% in men (p = 0.10). Prophylactic aspirin use was more common in older than in younger adults, in whites than in blacks, in those with a history of cardiovascular disease or hypercholesterolemia, and in health professionals and nonsmokers. Some individuals were apparently taking aspirin for "primary" prevention, although it has not yet been approved for that reason. Use of aspirin for cardiovascular disease prevention has been increasing and is likely to increase more rapidly over the next few years. This could favorably impact on mortality rates of cardiovascular disease, but untoward side effects of aspirin may be expected to increase as well.
阿司匹林预防缺血性心血管疾病的功效最近受到了广泛关注。为了确定阿司匹林用于心血管疾病预防的普及情况，明尼苏达心脏调查研究了1981年至1982年以及1985年至1986年双城成年人群体样本。在这4年期间，报告称用于心血管疾病预防的阿司匹林使用情况在女性中从0.6%增至2.4%（p小于0.05），在男性中从1.7%增至3.3%（p = 0.10）。预防性使用阿司匹林在老年人中比在年轻人中更常见，在白人中比在黑人中更常见，在有心血管疾病或高胆固醇血症病史的人群中以及在健康专业人员和不吸烟者中更常见。一些人显然在将阿司匹林用于“一级”预防，尽管尚未因其该用途获批。用于心血管疾病预防的阿司匹林使用一直在增加，并且在未来几年可能会更快增加。这可能会对心血管疾病死亡率产生有利影响，但阿司匹林的不良副作用预计也会增加。
